Anzeige
Mehr »
Login
Samstag, 27.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Nurexone Biologic: Jetzt diese wirklich einzigartige Chance ergreifen?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
599 Leser
Artikel bewerten:
(2)

Pace® Analytical: Pace Life Sciences Announces Successful Outcomes Following US FDA Inspection of Operations in San German, Puerto Rico

Long-standing reputation for robust quality is confirmed as company enters 2024

SAN GERMÁN, PR / ACCESSWIRE / March 28, 2024 / Pace® Life Sciences, LLC, a full-service FDA-registered central laboratory and contract development and manufacturing organization (CDMO), announced the receipt of an overall positive review from The Food & Drug Administration (FDA), following a three-day general inspection of the company's quality systems and client data delivery processes at its laboratory in San German, Puerto Rico.

PLS Logo

Lou Forcellini, Head of Quality Assurance at Pace® Life Sciences, shares, "The success of this inspection is a positive reflection of our entire laboratory network, including the strength of our quality leadership, the team of highly experienced laboratory professionals, and our commitment to data integrity and compliance through robust quality systems. More than five years have passed since our previous US FDA inspection in San German, and we have remained diligent. We host more than 60 client audits each year that challenge our system and ensure we are robust and up to date with current quality expectations."

The operation in Puerto Rico includes a team of more than 60 fully bilingual chemists and microbiologists who have decades of proven expertise and a strong track record supporting pharmaceutical and medical device clients from around the world. In 2023, this laboratory achieved an average turnaround time of 10 working days for client projects, a remarkable industry benchmark. With over 22,000 square feet of chemistry and microbiology laboratory space, this location is registered with both the US FDA and the US Drug Enforcement Agency (DEA). Primary services offered at this laboratory include:

  • Chemistry & Microbiology Laboratory Testing
  • Raw Material Clearance Programs
  • In-Process & Finished Product Testing
  • ICH Stability Programs
  • Facility Environmental Monitoring Programs
  • Cleaning Verification/Disinfectant Efficacy Studies

Pace® is a portfolio company of Leonard Green & Partners and Los Angeles-based Aurora Capital Partners.

ABOUT PACE® LIFE SCIENCES?

Pace® Life Sciences provides a full suite of contract CMC development, clinical trials materials manufacturing, regulatory compliance, consulting, and facility support services to the pharmaceutical, biopharmaceutical, and gene therapy industries. Our network of CDMO sites consists of GMP analytical testing laboratories and manufacturing support service centers. Our experienced, highly trained industry experts and our investment in state-of-the-art development and manufacturing facilities emphasize our commitment to efficiently advancing client programs through the clinic to commercialization. We are dedicated to delivering the best and most reliable services with positive customer experiences across all channels of our business. More at?pacelifesciences.com.

ABOUT PACE®

Pace® makes the world a safer, healthier place. Pace® people are committed to advancing the science of the pharmaceutical and biotechnology industries in our Life sciences laboratories and supporting businesses, industries, consulting firms, government agencies, and more in our Analytical Services Laboratories. Pace® offers local-level service backed by a national laboratory network. For customers with in-house labs, Pace® provides a range of professional services to keep their operations moving forward. Pace® people work in partnership with customers by providing the service, science and data they need to make critical decisions that benefit us all.

Contact Information:

Pam Bednar
Marketing Director
pam.bednar@pacelabs.com
612-297-0651

Chelsea Simpson
Associate Marketing Director
chelsea.simpson@pacelabs.com
860-338-3429

SOURCE: Pace® Life Sciences

.

View the original press release on newswire.com.

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2024 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.